Viking's obesity drug proves to be beneficial in clinical trials
Time : 30th of March 2023 12:28:35 PM
,
The injectable drug developed by Viking Therapeutics helped obese patients lose almost 8% of their body weight in a small phase 1 clinical trial. The 10 mg per week dose of the drug caused the largest weight loss. Viking's drug, VK2735, activates two insulin-stimulating hormones, which Eli Lily's drug also activates. Eli Lily's drug Mounjaro is in phase 3 trials now.
BiopharmadiveTags
obesity drug, injectable, Viking TherapeuticsRecent Posts
